See more : The Pulse Network, Inc. (TPNI) Income Statement Analysis – Financial Results
Complete financial analysis of Elevation Oncology, Inc. (ELEV) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Elevation Oncology, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Poly Union Chemical Holding Group Co., Ltd. (002037.SZ) Income Statement Analysis – Financial Results
- Samsung Fire & Marine Insurance Co., Ltd. (000815.KS) Income Statement Analysis – Financial Results
- Comcast Corporation (CTP2.DE) Income Statement Analysis – Financial Results
- CryptoStar Corp. (CSTR.V) Income Statement Analysis – Financial Results
- Light S.A. (LIGT3.SA) Income Statement Analysis – Financial Results
Elevation Oncology, Inc. (ELEV)
About Elevation Oncology, Inc.
Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. Elevation Oncology, Inc. was incorporated in 2019 and is based in New York, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 39.00K | 27.00K | 18.00K | 15.00K | 0.00 |
| Gross Profit | -39.00K | -27.00K | -18.00K | -15.00K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 25.43M | 78.72M | 23.60M | 15.48M | 5.34M |
| General & Administrative | 14.90M | 15.83M | 8.45M | 1.80M | 816.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 543.18K |
| SG&A | 14.90M | 15.83M | 8.45M | 1.80M | 544.00K |
| Other Expenses | 5.11M | -506.00K | 7.00K | 11.00K | 0.00 |
| Operating Expenses | 45.45M | 94.55M | 32.05M | 17.28M | 5.88M |
| Cost & Expenses | 45.45M | 94.55M | 32.05M | 17.28M | 5.88M |
| Interest Income | 3.90M | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 4.17M | 479.00K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 39.00K | 27.00K | 18.00K | 15.00K | 3.57M |
| EBITDA | -41.47M | -94.52M | -32.03M | -17.25M | -5.88M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -45.45M | -94.55M | -32.05M | -17.28M | -5.88M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -229.00K | -506.00K | 7.00K | 11.00K | 0.00 |
| Income Before Tax | -45.67M | -95.06M | -32.04M | -17.27M | -5.88M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 30.00K | 25.00K | -218.56K | -191.30K | -8.82K |
| Net Income | -45.70M | -95.08M | -32.04M | -17.27M | -5.88M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.34 | -4.09 | -1.38 | -0.73 | -0.25 |
| EPS Diluted | -1.34 | -4.09 | -1.38 | -0.73 | -0.25 |
| Weighted Avg Shares Out | 34.08M | 23.27M | 23.21M | 23.76M | 23.76M |
| Weighted Avg Shares Out (Dil) | 34.08M | 23.27M | 23.21M | 23.76M | 23.76M |
Elevation Oncology Announces Promising Initial Data from Phase 1 Clinical Trial Evaluating EO-3021 in Patients with Advanced Unresectable or Metastatic Solid Tumors Likely to Express Claudin 18.2
-- 42.8% confirmed ORR observed in Claudin 18.2-enriched subset of gastric and GEJ cancer -- -- EO-3021 demonstrated differentiated safety profile, with minimal MMAE-associated toxicities, including no neutropenia or peripheral neuropathy/ hypoesthesia -- -- Advancing into dose expansion portion of Phase...
Elevation Oncology Announces Planned Combination Strategy for EO-3021 in Patients with Gastric or Gastroesophageal Junction Cancer
-- Plan to evaluate EO-3021 in combination with ramucirumab and dostarlimab; entered into clinical supply agreements with Lilly and GSK, respectively -- -- Expect to initiate dosing in combination portion of the Phase 1 trial by year-end 2024 -- --...
Elevation Oncology to Present at the Citizens JMP Life Sciences Conference
BOSTON , May 7, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs,...
Elevation Oncology: Mid-2024 EO-3021 Data Could Get Ball Rolling
Results from the phase 1 study, using EO-3021 for the treatment of CLDN 18.2 expressing solid tumors, expected mid-Q3 of 2024; Additional data expected 1st half of 2025. HER3-ADC is another ADC being developed in the pipeline for the treatment...
Elevation Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business Achievements
-- Enrollment ongoing in Phase 1 clinical trial of EO-3021 in the U.S. and Japan; expect to announce initial safety and efficacy data by mid-3Q 2024, with additional data in 1H 2025 -- -- Presented preclinical proof-of-concept data for HER3-ADC...
Elevation Oncology: Continuing To Seek Footing As It Climbs (Rating Upgrade)
Elevation Oncology, Inc. has had a successful year, transitioning from the shelving of their seribantumab program to focusing on antibody-drug conjugates. Their flagship project, EO-3021, is a phase 1 study targeting Claudin-18.2 and has shown promising early results. Elevation Oncology...
Elevation Oncology Presents Preclinical Proof-of-Concept Data for HER3-ADC Program at AACR Annual Meeting 2024
-- On-track to nominate development candidate in 2024 -- BOSTON, April 8, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range...
All Three of Our Analysts Agree
Personalized health screening from a “smart toilet”
Elevation Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Achievements
--Expanded ongoing Phase 1 clinical trial of EO-3021 globally, dosing first patient in Japan; on track to provide update in mid-2024 and to report additional data in 1H 2025 -- -- Preclinical proof-of-concept data for HER3-ADC program to be presented...
Trim the Fat: 3 Overbought Stocks Poised for a Pullback
Recently, I watched portions of a YouTube video that tangentially but importantly related to overbought stocks to sell. An options trader boasted about an 80% success rate with his system, which sounded like nonsense.
Source: https://incomestatements.info
Category: Stock Reports